Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
2.200
+0.100 (4.76%)
At close: Oct 7, 2026, 4:00 PM EDT
2.020
-0.180 (-8.18%)
After-hours: Oct 7, 2026, 7:59 PM EDT
Lipocine Employees
Lipocine had 14 employees as of December 31, 2025. The number of employees decreased by 2 or -12.50% compared to the previous year. That makes Lipocine the world's 39,225th largest employer and 5,788th in the United States.
Employees
14
Change (1Y)
-2
Growth (1Y)
-12.50%
Revenue / Employee
$112,104
Profits / Employee
-$846,529
Market Cap
18.14M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | -2 | -12.50% |
| Dec 31, 2024 | 16 | -1 | -5.88% |
| Dec 31, 2023 | 17 | 0 | - |
| Dec 31, 2022 | 17 | 4 | 30.77% |
| Sep 30, 2022 | 17 | 4 | 30.77% |
| Jun 30, 2022 | 15 | 2 | 15.38% |
| Mar 31, 2022 | 13 | 0 | - |
| Dec 31, 2021 | 13 | 2 | 18.18% |
| Sep 30, 2021 | 13 | 2 | 18.18% |
| Jun 30, 2021 | 13 | - | - |
| Mar 31, 2021 | 13 | 1 | 8.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Palatin Technologies | 29 |
| Jasper Therapeutics | 22 |
| BioCardia | 21 |
| Kiora Pharmaceuticals | 13 |
| NewcelX | 12 |
| Allarity Therapeutics | 8 |
| Marker Therapeutics | 5 |
LPCN News
- 17 hours ago - Lipocine announces Health Canada approved TLANDO capsules - TheFly
- 18 hours ago - Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy - PRNewsWire
- 16 days ago - H.C. Wainwright sets $4 price target on Lipocine - TheFly
- 21 days ago - Lipocine Slides: Conference Presentation - Filings
- 23 days ago - Lipocine initiates Phase 3 study of LPCN 1154 for postpartum depression - TheFly
- 23 days ago - Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression - PRNewsWire
- 27 days ago - Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PRNewsWire
- 2 months ago - Lipocine reports Q2 EPS (32c) vs. (41c) last year - TheFly